Skip to content

The clinical benefit of allergy apps: evidence from a stratified, controlled intervention study in Augsburg, Germany

The clinical benefit of allergy apps: evidence from a stratified, controlled intervention study in Augsburg, Germany - PollDi-AUX

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035219
Enrollment
270
Registered
2025-01-08
Start date
2023-05-31
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J30.1

Interventions

Group 1: group 1 received a “placebo app” (general information on pollen and allergies only). The intervention period ran from May 31 to August 31, 2023. The participants used the app and the availabl
pollen and air pollutants forecast). The intervention period ran from May 31 to August 31, 2023. The participants used the app and the available functions on a daily basis.

Sponsors

Universität Augsburg, Lehrstuhl für Umweltmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: self-reported or doctor-diagnosed grass pollen allergy specific IgE against grass pollen (Phadia ImmunoCAP g6) = 0.7 self-reported seasonal symptoms to grass pollen with or without concomitant allergic asthma with or without allergy to other pollen types concomitant sensitisation (sIgE) to house dust mites is not an automatic exclusion criterion if no corresponding symptoms are reported written consent to participate in the study

Exclusion criteria

Exclusion criteria: known or suspected idiopathic/chronic rhinitis known chronic sinusitis known nasal polyposis long-term systemic therapy with immunosuppressants and/or steroids current and/or recent allergen-specific immunotherapy for grass pollen (since then current symptom severity cannot be estimated) perennial (year-round) allergy, e.g. to house dust mites or animal hair (with simultaneous exposure to animal hair) with significant symptoms planned trips during the study period that last longer than 2 weeks continuously, especially if the destination is >100 km away

Design outcomes

Primary

MeasureTime frame
Rhinitis-related quality of life (mini-RQLQ before-after intervention; feedback questionnaire)

Secondary

MeasureTime frame
Symptom severity (symptom score of app diary; only groups 2 and 3), exposure-relevant behavior (app diary), self-reported usefulness of the app (feedback QR), symptom forecast.

Countries

Germany

Contacts

Public ContactStefanie Gilles

Universität Augsburg

stefanie.gilles@med.uni-augsburg.de0821 5986412

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026